Company intelligence / Profile preview

Weishen Pharmaceutical Technology

Shanghai, Shanghai Shi, Chinacspc.com.hk ↗

Ownership: Private
Development stage: NDA

Overview

Weishen Pharmaceutical Technology is a Shanghai-based pharmaceutical company focused on the development of small molecule drugs for infectious diseases, with its lead asset VD1219 targeting the HBV capsid for chronic hepatitis B. The company has initiated at least one Phase 1 clinical trial evaluating safety, tolerability, pharmacokinetics, and preliminary antiviral activity in both healthy volunteers and patients with chronic hepatitis B in China. No clinical results have been published yet as the trial is ongoing/recruiting as of June 2025.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule drug
Industry: Biotech

Drug pipeline

1 asset

VD1219

Unknown

Beyond the preview

Go deeper on Weishen Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Weishen Pharmaceutical Technology.

Explore the full profile